Regulus Therapeutics gain on FDA nod for kidney disorder therapy study

Regulus Therapeutics

11/05/2022 17:09

** Drug developer's shares  RGLS.O  rise ~43.2% to $0.24
    ** Co says U.S. FDA has accepted its application to start
clinical study of its experimental kidney disorder treatment,
RGLS8429  urn:newsml:reuters.com:*:nPn2B5MV7a
    ** RGLS8429 is being developed as a potential treatment for
Autosomal Dominant Polycystic Kidney Disease (ADPKD), an
inherited disorder in which clusters of cysts develop in kidneys
    ** Co plans to initiate early-stage study in healthy
volunteers in Q2 and expects data in H2 of this year
    ** Also plans to initiate dosing in patients with ADPKD in
H2

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))